// App-Quantinova.ai

2888 : Identification of Prognostic Immunophenotypes at First Diagnosis in Patients with Acute Myeloid Leukemia (AML) By a Standardized Multicolor Flow Cytometry (MFC) Panel Originally Designed to Detect Measurable Residual Disease (MRD) at Follow-up

Researchers

Presenter

  • Maximilian Alexander A Rohnert

Principal Investigators

  • Michael Kramer

  • Philipp Ensel

  • Nadja Holtschke

  • Christoph Rollig

  • Martin Bornhuser

  • Veit Buecklein

  • Marion Subklewe

  • Stefan W Krause

  • Simon Voelkl

  • Tobias Berg

  • Michael A Rieger

  • Cornelia Brendel

  • Jrg Hoffmann

  • Nicole Hofmeister-Mielke

  • Richard F. Schlenk

  • Sylvie D Freeman

  • Uta Oelschlgel

Medical Centers

  • Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany

  • Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany

  • German Cancer Research Centre, Heidelberg, Germany

  • German Cancer Consortium (DKTK), Heidelberg, Germany

  • Department of Hematology and Oncology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany

  • Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany

  • Department of Medicine III, University Hospital Grosshadern/LMU, Munich, Germany

  • Department of Medicine , University Hospital Erlangen, Erlangen, Germany

  • Department of Medicine, Hematology/Oncology, Goethe University of Frankfurt, Frankfurt, Germany

  • Stem Cell and Cancer Research Institute and Department of Oncology, McMaster University, Hamilton, ON, Canada

  • Department of Medicine, Hematology/Oncology, Goethe University of Frankfurt, Frankfurt, Germany

  • Department of Internal Medicine and Hematology, Philipps University Marburg, Marburg, Germany

  • Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany

  • Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom

Locations

  • Germany

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • Cluster of Differentiation 34

  • Cluster of differentiation 45

  • Cluster of Differentiation 56

  • Cluster of differentiation 7

  • Human Leukocyte Antigen – DR isotype

  • KIT Proto-Oncogene, Receptor Tyrosine Kinase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved